Search results
Aug 18, 2022 · The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued updated interim recommendations for the use of the Moderna COVID-19 (mRNA-1273) vaccine against COVID-19. This article provides a summary of those interim recommendations; you may access the full guidance document here. Here is what you need to know.
Sep 22, 2021 · The phase 3 trial of mRNA-1273, a lipid nanoparticle–encapsulated mRNA expressing the prefusion-stabilized spike glycoprotein of SARS-CoV-2, 11 showed a 94.1% vaccine efficacy against Covid-19 ...
Jul 14, 2020 · The mRNA-1273 vaccine candidate, manufactured by Moderna, encodes the S-2P antigen, consisting of the SARS-CoV-2 glycoprotein with a transmembrane anchor and an intact S1–S2 cleavage site.
Sep 15, 2021 · In the mRNA-1273 booster phase, 20 participants who had received two injections of 100-μg mRNA-1273 completed the blinded phase and who went on to receive a single booster dose of 50-μg mRNA ...
Feb 24, 2021 · Manufacturer: ModernaTX, Inc. The Moderna COVID-19 vaccine is a messenger RNA (mRNA) based vaccine against coronavirus disease 2019 (COVID-19). The host cells receive the instruction from the mRNA to produce protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory ...
Sep 20, 2023 · The bivalent (original and Omicron BA.4/BA.5) mRNA-1273 COVID-19 vaccine was authorized to offer broader protection against COVID-19. We conducted a matched cohort study to evaluate the ...
mRNA-1273 has not yet been established; potential adverse impacts due to the global COVID -19 pandemic such as delays in clinical trials, preclinical work, overall operations, regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy;
